First communication on the efficacy of combined177Lutetium-PSMA with immunotherapy outside prostate cancer

• DOI: 10.1136/jitc-2022-005383
• Publication Date: 2022-10-26T14:10:54Z
• Authors: Antonia Digklia; Sarah Boughdad; Krisztian Homicsko; Clarisse Dromain; Mounir Trimech; Ana Dolcan; Solange Peters; John Prior; Niklaus Schaefer
• Keywords: Male; Radioisotopes; 0301 basic medicine; Communication; Prostate; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Prostatic Neoplasms; Case Report; Lutetium; Male; Humans; Lutetium/therapeutic use; Lutetium/adverse effects; Prostate/pathology; Radioisotopes/therapeutic use; Prostatic Neoplasms/drug therapy; Immunotherapy; Communication; Radioimmunotherapy; Sarcoma; Therapies, Investigational; 3. Good health; 03 medical and health sciences; Humans; Immunotherapy; RC254-282

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is a validated treatment option for patients with advanced prostate cancer. Although PSMA expression is not limited to prostate tissue, little is known about its relevance to other types of cancer. Here, we present a case report of a patient with uterine leiomyosarcoma that is progressing while on immunotherapy and treated with177Lu-PSMA radionuclide therapy. We report for the first time that177Lu-PSMA radionuclide therapy combined with immunotherapy outside of prostate cancer. We did observe post-treatment reduction of tumor growth rate, although we did not notice disease response based on RECIST criteria. We suggest that177Lu-PSMA treatment especially combined with immunotherapy may be an option for patients with cancer without other therapeutic options. Insights:177Lu-PSMA radionuclide therapy should be considered for any tumor stained positive for PSMA.